Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB127 Ultrasound Contrast Agent in Suspected Obstructive Coronary Artery Disease
NCT00584896Phase 3Terminated
- Sponsor
- POINT Biomedical
- Start
- Oct 2007
- Primary completion
- Jul 2008
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 3 trial of PB127 in coronary artery disease (CAD), sponsored by POINT Biomedical. Started Oct 2007; status: terminated.
02
Drugs
PB127
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00584896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00584896.